Bank of New York Mellon’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Bank of New York Mellon’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-42,124	Closed	-$2.32M	–	4657
2022 Q2	$2.32M	Buy	42,124 +19,029	+82%	+$999K	﹤0.01%	2750
2022 Q1	$740K	Buy	+23,095	New	+$663K	﹤0.01%	3490
2018 Q3	–	Sell	-1,875	Closed	-$222K	–	4279
2018 Q2	$222K	Hold	1,875	–	–	﹤0.01%	3902
2018 Q1	$155K	Hold	1,875	–	–	﹤0.01%	3981
2017 Q4	$280K	Buy	+1,875	New	+$180K	﹤0.01%	3834
2016 Q2	–	Sell	-428	Closed	-$115K	–	4364
2016 Q1	$115K	Sell	428 -10	-2%	-$3.19K	﹤0.01%	3935
2015 Q4	$264K	Buy	+438	New	+$296K	﹤0.01%	3776

Other funds holding SRRA

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Bank of New York Mellon's SRRA Position: Q3 2022 in Review

Bank of New York Mellon sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2022, closing a stake of 42,124 shares — an estimated $2.32M sold.

Bank of New York Mellon first reported a position in SRRA in Q4 2015 and held it in 7 quarters. The position peaked at $2.32M in Q2 2022. 1 fund tracked by Wall St. Rank holds SRRA as of Q3 2022.

Bank of New York Mellon reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Bank of New York Mellon sold 42,124 Sierra Oncology, Inc. Common Stock shares in Q3 2022, an estimated $2.32M.
Bank of New York Mellon first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2015 and held it in 7 quarters.
Bank of New York Mellon's Sierra Oncology, Inc. Common Stock position peaked at $2.32M in Q2 2022.
1 fund tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2022.

Based on Bank of New York Mellon's 13F filing for Q3 2022, filed 14 Nov 2022.